The extensive pretrial proceedings mean the first Ozempic bellwether trials are unlikely to begin until at least 2026 or 2027.
With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.
Lawsuit claims Novo Nordisk's failures to warn about the risk of gastroparesis and Ileus from Ozempic were "wanton, willful, fraudulent, reckless acts."
The Court may soon allow future lawsuits over Ozempic, Wegovy, Mounjaro and other GLP-1s to be brought using a Short Form Complaint, adopting allegations from the MDL Master Complaint.
New GLP-1 warnings will urge users to inform their doctors before surgery if they are taking the diabetes and weight loss drugs.
Court will examine general causation, along with other “cross cutting” issues, before selecting any individual Ozempic gastroparesis lawsuits for trial workup.
Researchers have found that users of Ozempic, Mounjaro and similar drugs are less likely to experience opioid overdoses or alcoholism.
Lawsuit indicates that the gastroparesis diagnosis from Ozempic was confirmed after plaintiff underwent a gastric emptying test, which is evidence not present in many other claims in the litigation.
Inadequate bowel prep due to side effects of Ozempic and Mounjaro carries significant risk of missed lesions, canceled procedures and other complications.
Novo Nordisk allegedly knew for years about the risk that Ozempic and Rybelsus may cause ileus and other severe gastrointestinal side effects, but failed to warn doctors or patients.
